Skip to main content

Table 3 Association between lncRNA MEG3 polymorphisms and pCR rate in different comparison models

From: Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer

SNP Dominant model Genotypes pCR n (%) Non-pCR n (%) P Dominant model Recessive model Additive model
  OR(95% CI) P OR(95% CI) P OR(95% CI) P
rs10132552 TT 22(28.2) 56(71.8) 0.012* 2.396(1.202~4.777) 0.013* 1.72(0.412~7.181) 0.457 TC 2.376(1.164~4.847) 0.017*
  TC + CC 32(48.5) 34(51.5)       CC 2.545(0.585~11.082) 0.213
rs941576 AA 22(31.9) 47(68.1) 0.182 1.59(0.803~3.146) 0.183 2.194(0.563~8.554) 0.258 AG 1.479(0.731~2.994) 0.277
  AG + GG 32(42.7) 43(57.3)       GG 2.67(0.653~10.926) 0.172
rs7158663 GG 28(34.1) 54(65.9) 0.339 1.393(0.705~2.75) 0.34 2.959(0.678~12.916) 0.149 AG 1.227(0.602~2.503) 0.573
  AG + AA 26(41.9) 36(58.1)       AA 3.214(0.716~14.44) 0.128
  1. Abbreviations: pCR pathological complete remission, OR odds ratio
  2. *P < 0.05